<p>O Shaughnessy Asset Management LLC 在最近向证券交易委员会（SEC）提交的文件中表示，在第四季度将其在辉瑞公司（NYSE:PFE - 免费报告）的持股减少了 55.6%。该公司在此期间出售了 254,639 股后，持有 203,518 股辉瑞的股票。O Shaughnessy Asset Management LLC 在辉瑞的持股在最近一个季度末的价值为 5,399,000 美元。</p>
<ul>
<li>作为摩根大通提升吉利德评级的两只医疗股</li>
</ul>
<p>其他机构投资者最近也调整了对该公司的持股。退休财富解决方案公司在第四季度购买了约 26,000 美元的新辉瑞股份。Rialto Wealth Management LLC 在第四季度购买了约 26,000 美元的辉瑞股份。Kohmann Bosshard Financial Services LLC 在第四季度收购了约 28,000 美元的辉瑞股份。Noble Wealth Management PBC 在第四季度购买了价值 31,000 美元的辉瑞股份。最后，Curio Wealth LLC 在第四季度收购了价值 32,000 美元的辉瑞股份。机构投资者持有该公司 68.36% 的股票。</p>
<h2>分析师设定新目标价</h2>
<p>辉瑞近期成为多份分析师报告的主题。Truist Financial 在 12 月 18 日的研究报告中将辉瑞的目标价从 36.00 美元下调至 32.00 美元，并对该股票给予 “买入” 评级。汇丰全球研究在 3 月 10 日的报告中将辉瑞的评级提升至 “强力买入”。瑞银集团在 1 月 8 日的报告中将辉瑞的目标价从 31.00 美元下调至 29.00 美元，并对该公司给予 “中性” 评级。古根海姆在 3 月 18 日的研究报告中重申了对辉瑞的 “买入” 评级。最后，花旗在 1 月 28 日的研究报告中将辉瑞的目标价从 30.00 美元下调至 29.00 美元，并对该公司给予 “中性” 评级。一位分析师对该股票给予了卖出评级，七位给予了持有评级，六位给予了买入评级，三位给予了强力买入评级。根据 MarketBeat 的数据，该股票的平均评级为 “适度买入”，平均目标价为 31.92 美元。</p>
<ul>
<li>Viking Therapeutics：GLP-1 制造商会在批准前被收购吗？</li>
</ul>
<p><strong>查看我们最新的辉瑞股票分析</strong></p>
<h2>内部人士下注</h2>
<p>在辉瑞的其他新闻中，董事 Ronald E. Blaylock 于 2 月 13 日购买了 19,457 股该公司的股票。每股平均购买价格为 25.65 美元，总交易额为 499,072.05 美元。收购完成后，该董事现在持有 27,707 股公司股票，价值约 710,684.55 美元。这笔交易代表了他们持股的 235.84% 的增长。该购买在向证券交易委员会提交的文件中披露，文件可在此链接查看。内部人士持有该公司 0.06% 的股票。</p>
<h2>辉瑞股价下跌 3.2%</h2>
<ul>
<li>这些股票的收益未达预期，但下个季度将反弹</li>
</ul>
<p>NYSE PFE 周三开盘价为 24.53 美元。辉瑞公司的 12 个月最低价为 24.48 美元，最高价为 31.54 美元。该公司的 50 日移动平均线为 26.00 美元，200 日移动平均线为 26.84 美元。公司流动比率为 0.73，当前比率为 1.00，债务与股本比率为 0.63。公司的市值为 1390.9 亿美元，市盈率为 17.39，市盈增长比率为 0.64，贝塔值为 0.61。</p>
<p>辉瑞（NYSE:PFE - 获取免费报告）最近于 2 月 4 日发布了季度财报。这家生物制药公司报告每股收益为 0.63 美元，超出市场普遍预期的 0.48 美元，超出幅度为 0.15 美元。辉瑞的股本回报率为 19.47%，净利润率为 12.62%。该公司季度收入为 177.6 亿美元，而分析师预期为 172.6 亿美元。在去年同期，该公司的每股收益为 0.10 美元。该公司的季度收入较去年同期增长了 24.7%。整体来看，卖方分析师预计辉瑞公司在当前财政年度将发布 2.95 的每股收益。</p>
<h2>辉瑞公司简介</h2>
<p>（免费报告）</p>
<p>辉瑞公司在美国、欧洲及国际市场上发现、开发、生产、营销、分销和销售生物制药产品。该公司在多个治疗领域提供药物和疫苗，包括心血管代谢、偏头痛和女性健康，旗下品牌包括 Eliquis、Nurtec ODT/Vydura、Zavzpret 和 Premarin 系列；在满足医疗需求的传染病领域，旗下品牌包括 Prevnar 系列、Abrysvo、Nimenrix、FSME/IMMUN-TicoVac 和 Trumenba；以及 COVID-19 预防和治疗，以及未来潜在的 mRNA 和抗病毒产品，旗下品牌包括 Comirnaty 和 Paxlovid。</p>
<h2>推荐故事</h2>
<ul>
<li>我们更看好的五只股票超过辉瑞</li>
<li>最大的股票亏损者 - 今日最大百分比下跌者</li>
<li>D-Wave：量子霸权后出现多种应用案例</li>
<li>顶级生物科技股票：探索创新机会</li>
<li>亚马逊回落至关键支撑线：这是如何操作的</li>
<li>什么是国债？</li>
<li>巴菲特削减股票，但仍继续购买这只股票</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPVBGRQ?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPVBGRQ"/></p>
<p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快和最准确的报道。此故事在发布前已由 MarketBeat 的编辑团队审核。如对该故事有任何问题或意见，请发送电子邮件至 contact@marketbeat.com。</em></p>
<h2>你现在应该投资 1,000 美元在辉瑞吗？</h2>
<p>在考虑辉瑞之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已经识别出五只顶级分析师正在悄悄向客户推荐的股票，建议在更广泛的市场注意到之前购买……而辉瑞并不在名单上。</p>
<p>虽然辉瑞目前在分析师中获得了适度买入评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

辉瑞

<p>O Shaughnessy Asset Management LLC 已将其在辉瑞公司（NYSE:PFE）的持股比例减少了 55.6%，在第四季度出售了 254,639 股，剩余 203,518 股，价值 540 万美元。其他机构投资者也增加了对辉瑞的持股。分析师对该股票的评级不一，目标价格范围在 29 美元到 32 美元之间。辉瑞最近的财报显示每股盈利 0.63 美元，超出预期，收入为 177.6 亿美元，同比增长 24.7%</p>

<p>O Shaughnessy Asset Management LLC decreased its position in shares of Pfizer Inc. (NYSE:PFE - Free Report) by 55.6% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 203,518 shares of the biopharmaceutical company's stock after selling 254,639 shares during the period. O Shaughnessy Asset Management LLC's holdings in Pfizer were worth $5,399,000 at the end of the most recent quarter.</p>
<div class="lb-trans"><p>O Shaughnessy Asset Management LLC 在最近向证券交易委员会（SEC）提交的文件中表示，在第四季度将其在辉瑞公司（NYSE:PFE - 免费报告）的持股减少了 55.6%。该公司在此期间出售了 254,639 股后，持有 203,518 股辉瑞的股票。O Shaughnessy Asset Management LLC 在辉瑞的持股在最近一个季度末的价值为 5,399,000 美元。</p>
</div><ul>
<li>2 Healthcare Stocks to Watch as JPMorgan Boosts Gilead Rating</li>
</ul>
<div class="lb-trans"><ul>
<li>作为摩根大通提升吉利德评级的两只医疗股</li>
</ul>
</div><p>Other institutional investors also recently modified their holdings of the company. Retirement Wealth Solutions LLC bought a new stake in Pfizer in the 4th quarter valued at about $26,000. Rialto Wealth Management LLC bought a new stake in shares of Pfizer in the fourth quarter valued at approximately $26,000. Kohmann Bosshard Financial Services LLC acquired a new stake in Pfizer during the fourth quarter worth approximately $28,000. Noble Wealth Management PBC bought a new position in Pfizer during the 4th quarter worth $31,000. Finally, Curio Wealth LLC acquired a new position in Pfizer in the 4th quarter valued at $32,000. Institutional investors own 68.36% of the company's stock.</p>
<div class="lb-trans"><p>其他机构投资者最近也调整了对该公司的持股。退休财富解决方案公司在第四季度购买了约 26,000 美元的新辉瑞股份。Rialto Wealth Management LLC 在第四季度购买了约 26,000 美元的辉瑞股份。Kohmann Bosshard Financial Services LLC 在第四季度收购了约 28,000 美元的辉瑞股份。Noble Wealth Management PBC 在第四季度购买了价值 31,000 美元的辉瑞股份。最后，Curio Wealth LLC 在第四季度收购了价值 32,000 美元的辉瑞股份。机构投资者持有该公司 68.36% 的股票。</p>
</div><h2>Analysts Set New Price Targets</h2>
<div class="lb-trans"><h2>分析师设定新目标价</h2>
</div><p>PFE has been the topic of a number of recent analyst reports. Truist Financial decreased their price target on Pfizer from $36.00 to $32.00 and set a &#34;buy&#34; rating on the stock in a research report on Wednesday, December 18th. Hsbc Global Res raised shares of Pfizer to a &#34;strong-buy&#34; rating in a report on Monday, March 10th. UBS Group cut their price target on shares of Pfizer from $31.00 to $29.00 and set a &#34;neutral&#34; rating for the company in a report on Wednesday, January 8th. Guggenheim reissued a &#34;buy&#34; rating on shares of Pfizer in a research note on Tuesday, March 18th. Finally, Citigroup cut their target price on Pfizer from $30.00 to $29.00 and set a &#34;neutral&#34; rating for the company in a research note on Tuesday, January 28th. One analyst has rated the stock with a sell rating, seven have given a hold rating, six have issued a buy rating and three have issued a strong buy rating to the company. According to data from MarketBeat, the stock has an average rating of &#34;Moderate Buy&#34; and an average price target of $31.92.</p>
<div class="lb-trans"><p>辉瑞近期成为多份分析师报告的主题。Truist Financial 在 12 月 18 日的研究报告中将辉瑞的目标价从 36.00 美元下调至 32.00 美元，并对该股票给予 “买入” 评级。汇丰全球研究在 3 月 10 日的报告中将辉瑞的评级提升至 “强力买入”。瑞银集团在 1 月 8 日的报告中将辉瑞的目标价从 31.00 美元下调至 29.00 美元，并对该公司给予 “中性” 评级。古根海姆在 3 月 18 日的研究报告中重申了对辉瑞的 “买入” 评级。最后，花旗在 1 月 28 日的研究报告中将辉瑞的目标价从 30.00 美元下调至 29.00 美元，并对该公司给予 “中性” 评级。一位分析师对该股票给予了卖出评级，七位给予了持有评级，六位给予了买入评级，三位给予了强力买入评级。根据 MarketBeat 的数据，该股票的平均评级为 “适度买入”，平均目标价为 31.92 美元。</p>
</div><ul>
<li>Viking Therapeutics: Could GLP-1 Maker Be Acquired Pre-Approval?</li>
</ul>
<div class="lb-trans"><ul>
<li>Viking Therapeutics：GLP-1 制造商会在批准前被收购吗？</li>
</ul>
</div><p><strong>View Our Latest Stock Analysis on PFE</strong></p>
<div class="lb-trans"><p><strong>查看我们最新的辉瑞股票分析</strong></p>
</div><h2>Insiders Place Their Bets</h2>
<div class="lb-trans"><h2>内部人士下注</h2>
</div><p>In other Pfizer news, Director Ronald E. Blaylock purchased 19,457 shares of the business's stock in a transaction dated Thursday, February 13th. The shares were bought at an average price of $25.65 per share, for a total transaction of $499,072.05. Following the completion of the acquisition, the director now owns 27,707 shares in the company, valued at approximately $710,684.55. This trade represents a 235.84 % increase in their ownership of the stock. The purchase was disclosed in a document filed with the Securities &amp; Exchange Commission, which is available at this link. Insiders own 0.06% of the company's stock.</p>
<div class="lb-trans"><p>在辉瑞的其他新闻中，董事 Ronald E. Blaylock 于 2 月 13 日购买了 19,457 股该公司的股票。每股平均购买价格为 25.65 美元，总交易额为 499,072.05 美元。收购完成后，该董事现在持有 27,707 股公司股票，价值约 710,684.55 美元。这笔交易代表了他们持股的 235.84% 的增长。该购买在向证券交易委员会提交的文件中披露，文件可在此链接查看。内部人士持有该公司 0.06% 的股票。</p>
</div><h2>Pfizer Trading Down 3.2 %</h2>
<div class="lb-trans"><h2>辉瑞股价下跌 3.2%</h2>
</div><ul>
<li>These Stocks Missed on Earnings, But Will Rebound Next Quarter</li>
</ul>
<div class="lb-trans"><ul>
<li>这些股票的收益未达预期，但下个季度将反弹</li>
</ul>
</div><p>NYSE PFE opened at $24.53 on Wednesday. Pfizer Inc. has a twelve month low of $24.48 and a twelve month high of $31.54. The business's fifty day moving average is $26.00 and its 200 day moving average is $26.84. The company has a quick ratio of 0.73, a current ratio of 1.00 and a debt-to-equity ratio of 0.63. The company has a market cap of $139.09 billion, a price-to-earnings ratio of 17.39, a price-to-earnings-growth ratio of 0.64 and a beta of 0.61.</p>
<div class="lb-trans"><p>NYSE PFE 周三开盘价为 24.53 美元。辉瑞公司的 12 个月最低价为 24.48 美元，最高价为 31.54 美元。该公司的 50 日移动平均线为 26.00 美元，200 日移动平均线为 26.84 美元。公司流动比率为 0.73，当前比率为 1.00，债务与股本比率为 0.63。公司的市值为 1390.9 亿美元，市盈率为 17.39，市盈增长比率为 0.64，贝塔值为 0.61。</p>
</div><p>Pfizer (NYSE:PFE - Get Free Report) last released its quarterly earnings results on Tuesday, February 4th. The biopharmaceutical company reported $0.63 earnings per share for the quarter, topping the consensus estimate of $0.48 by $0.15. Pfizer had a return on equity of 19.47% and a net margin of 12.62%. The company had revenue of $17.76 billion for the quarter, compared to analysts' expectations of $17.26 billion. During the same period in the previous year, the business posted $0.10 earnings per share. The business's quarterly revenue was up 24.7% compared to the same quarter last year. As a group, sell-side analysts expect that Pfizer Inc. will post 2.95 EPS for the current fiscal year.</p>
<div class="lb-trans"><p>辉瑞（NYSE:PFE - 获取免费报告）最近于 2 月 4 日发布了季度财报。这家生物制药公司报告每股收益为 0.63 美元，超出市场普遍预期的 0.48 美元，超出幅度为 0.15 美元。辉瑞的股本回报率为 19.47%，净利润率为 12.62%。该公司季度收入为 177.6 亿美元，而分析师预期为 172.6 亿美元。在去年同期，该公司的每股收益为 0.10 美元。该公司的季度收入较去年同期增长了 24.7%。整体来看，卖方分析师预计辉瑞公司在当前财政年度将发布 2.95 的每股收益。</p>
</div><h2>Pfizer Company Profile</h2>
<div class="lb-trans"><h2>辉瑞公司简介</h2>
</div><p>(Free Report)</p>
<div class="lb-trans"><p>（免费报告）</p>
</div><p>Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.</p>
<div class="lb-trans"><p>辉瑞公司在美国、欧洲及国际市场上发现、开发、生产、营销、分销和销售生物制药产品。该公司在多个治疗领域提供药物和疫苗，包括心血管代谢、偏头痛和女性健康，旗下品牌包括 Eliquis、Nurtec ODT/Vydura、Zavzpret 和 Premarin 系列；在满足医疗需求的传染病领域，旗下品牌包括 Prevnar 系列、Abrysvo、Nimenrix、FSME/IMMUN-TicoVac 和 Trumenba；以及 COVID-19 预防和治疗，以及未来潜在的 mRNA 和抗病毒产品，旗下品牌包括 Comirnaty 和 Paxlovid。</p>
</div><h2>Recommended Stories</h2>
<div class="lb-trans"><h2>推荐故事</h2>
</div><ul>
<li>Five stocks we like better than Pfizer</li>
<li>Biggest Stock Losers - Today’s Biggest Percentage Decliners</li>
<li>D-Wave: Multiple Use Cases Emerge Following Quantum Supremacy</li>
<li>Top Biotech Stocks: Exploring Innovation Opportunities</li>
<li>Amazon Falls Back to a Key Support Line: Here's How to Play It</li>
<li>What Are Treasury Bonds?</li>
<li>Buffett Trims Equities, But Still Keeps Buying This Stock</li>
</ul>
<div class="lb-trans"><ul>
<li>我们更看好的五只股票超过辉瑞</li>
<li>最大的股票亏损者 - 今日最大百分比下跌者</li>
<li>D-Wave：量子霸权后出现多种应用案例</li>
<li>顶级生物科技股票：探索创新机会</li>
<li>亚马逊回落至关键支撑线：这是如何操作的</li>
<li>什么是国债？</li>
<li>巴菲特削减股票，但仍继续购买这只股票</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPVBGRQ" alt="" original-src="https://www.marketbeat.com/scripts/SECFilingChart.ashx?Prefix=NYSE&amp;Symbol=PFE"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快和最准确的报道。此故事在发布前已由 MarketBeat 的编辑团队审核。如对该故事有任何问题或意见，请发送电子邮件至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Pfizer Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1,000 美元在辉瑞吗？</h2>
</div><p>Before you consider Pfizer, you'll want to hear this.</p>
<div class="lb-trans"><p>在考虑辉瑞之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Pfizer wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已经识别出五只顶级分析师正在悄悄向客户推荐的股票，建议在更广泛的市场注意到之前购买……而辉瑞并不在名单上。</p>
</div><p>While Pfizer currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然辉瑞目前在分析师中获得了适度买入评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

O Shaughnessy Asset Management LLC Sells 254,639 Shares of Pfizer Inc. (NYSE:PFE)

- O Shaughnessy Asset Management LLC 在第四季度减持辉瑞股份 55.6%。  
- 该公司持有辉瑞 203,518 股，市值约为 539 万美元。  
- 辉瑞最新季度每股收益为 0.63 美元，超出预期。  

O Shaughnessy 资产管理公司出售辉瑞公司（纽约证券交易所代码：PFE）254,639 股股票